英文名稱phospho-B-Raf (Ser444)
中文名稱 Anti-BRD7/鼻咽癌相關(guān)轉(zhuǎn)錄調(diào)節(jié)蛋白抗體

別    名94 kDa B raf protein; B raf 1; B Raf proto oncogene serine threonine protein kinase; BRAF 1; Braf; BRAF1; cRmil; MGC126806; MGC138284; Murine sarcoma viral (v-raf) oncogene homolog B1; Murine sarcoma viral v raf oncogene homolog B1; p94; RAFB 1; RAFB1; v raf murine sarcoma viral oncogene homolog B1; FLJ95109; BRAF_HUMAN.
規(guī)格0.1ml  
產(chǎn)品類型磷酸化抗體 
研究領(lǐng)域腫瘤  細胞生物  免疫學(xué)  信號轉(zhuǎn)導(dǎo)  細胞凋亡  轉(zhuǎn)錄調(diào)節(jié)因子  
抗體來源Rabbit
克隆類型Polyclonal
交叉反應(yīng)Human, Mouse, Rat, Chicken, Dog, Pig, Horse, Rabbit, 
產(chǎn)品應(yīng)用WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)） 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量94kDa
細胞定位細胞核 細胞漿 細胞膜 
性    狀Lyophilized or Liquid
濃    度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human B-Raf around the phosphorylation site of Ser444
亞    型IgG
純化方法affinity purified by Protein A
儲 存 液0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
保存條件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
Anti-BRD7/鼻咽癌相關(guān)轉(zhuǎn)錄調(diào)節(jié)蛋白抗體he Raf kinases are important intermediates in signal transduction. Raf protein family members, including A Raf and B Raf, have intrinsic serine/threonine kinase activity. Interaction between Ras proteins and Raf proteins results in Raf-mediated phosphorylation and activation of MEK (also known as MAP kinase kinase). Defects in BRAF are involved in a wide range of cancers. B-Raf is a serine/threonine protein kinase that acts as a signal transducer from membrane-associated receptors to nuclear transcription factors. 1 BRAF is important for the regulation of cell proliferation and determination of cell fate during embryogenesis. BRAF acts downstream of Ras and upstream of MEK in the Ras-Raf-MEK-ERK signal transduction pathway, which is a conserved RAS-activated protein kinase cascade that regulates cell growth, proliferation, and differentiation in response to growth factors, cytokines, and hormones.

Function:
Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.

Subunit:
Monomer. Homodimer. Heterodimerizes with RAF1, and the heterodimer possesses a highly increased kinase activity compared to the respective homodimers or monomers. Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 activation can induce a negative feedback that promotes the dissociation of the heterodimer by phosphorylating BRAF at Thr-753. Found in a complex with at least BRAF, HRAS1, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the interaction mediates the formation of a ternary complex with RAF1, a ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH.

Subcellular Location:
Nucleus. Cytoplasm. Cell membrane.

Tissue Specificity:
Brain and testis.

Post-translational modifications:
Phosphorylation at Ser-365 by SGK1 inhibits its activity.
Methylation at Arg-671 decreases stability and kinase activity. 
Ubiquitinated by RNF149; which leads to proteasomal degradation.

DISEASE:
Note=Defects in BRAF are found in a wide range of cancers. 
Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:114500]. 
Defects in BRAF are involved in lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. 
Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. 
Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant. 
Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:613706]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hyperorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable inlectual deficits. 
Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:613707]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hyperorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. 
Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.

Similarity:
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily. 
Contains 1 phorbol-ester/DAG-type zinc finger. 
Contains 1 protein kinase domain. 
Contains 1 RBD (Ras-binding) domain.

Gene ID:
673

Database links:
Entrez Gene: 673 Human
Entrez Gene: 109880 Mouse
Entrez Gene: 114486 Rat
Omim: 164757 Human
SwissProt: P15056 Human
SwissProt: P28028 Mouse
Unigene: 550061 Human
Unigene: 245513 Mouse

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

BRAF蛋白是有絲分裂原活化的蛋白激酶/細胞外信號調(diào)節(jié)激酶途徑蛋白。正常的B-Raf蛋白的功能是傳遞來自細胞膜的信號,在Ras-Raf-MEK-ERK信號轉(zhuǎn)導(dǎo)調(diào)節(jié)途徑中有著重要的作用。
BRAF是一種在癌細胞的生長和存活中起到關(guān)鍵作用的蛋白質(zhì),并且在大多數(shù)惡性黑素瘤患者和少數(shù)結(jié)腸癌、乳腺癌和肺癌患者中發(fā)生突變，目前BRAF也用于惡性黑素瘤和腫瘤的研究。

人參皂苷Rb1    Ginsenoside Rb1    HPLC≥98%    20mg/支    41753-43-9

人參皂苷Rb2    Ginsenoside Rb2    HPLC≥98%    20mg/支    11021-13-9
人參皂苷Rb3    Ginsenoside Rb3    HPLC≥98%    20mg/支    68406-26-8
人參皂苷Rg1    Ginsenoside Rg1    HPLC≥98%    20mg/支    22427-39-0
人參皂苷Rg2    Ginsenoside Rg2    HPLC≥98%    20mg/支    52286-74-5
人參皂苷Rg3    Ginsenoside Rg3    HPLC≥98%    20mg/支    14197-60-5
人參皂苷Rh1    Ginsenoside Rh1    HPLC≥98%    20mg/支    63223-86-9
人參皂苷Rh2    Ginsenoside Rh2    HPLC≥98%    20mg/支    78214-33-2
擬人參皂苷Rh2    Pseudoginsenoside Rh2    HPLC≥98%    5mg/支    1370264-16-6
人參皂苷Rh3    Ginsenoside Rh3    HPLC≥98%    20mg/支    105558-26-7
人參皂苷Rc    Ginsenoside Rc    HPLC≥98%    20mg/支    11021-14-0
人參皂苷Re    Ginsenoside Re    HPLC≥98%    20mg/支    52286-59-6
人參皂苷Rd    Ginsenoside Rd    HPLC≥98%    20mg/支    52705-93-8
人參皂苷Rf    Ginsenoside- Rf    HPLC≥98%    20mg/支    52286-58-5
擬人參皂苷RT5    Pseudoginsenoside-RT5    HPLC≥98%    20mg/支    98474-78-3
原人參三醇    Protopanaxatriol    HPLC≥98%    20mg/支    34080-08-5
(R型)人參皂苷Rh1    Ginsenoside Rh1    HPLC≥98%    20mg/支    
(R型)人參皂苷Rh2    Ginsenoside Rh2    HPLC≥98%    20mg/支    112246-15-8
(R型)人參皂苷Rg2    Ginsenoside Rg2    HPLC≥98%    20mg/支    80952-72-3
(R型)人參皂苷Rg3    Ginsenoside Rg3    HPLC≥98%    20mg/支    38243-03-7
(R型)原人參三醇    Protopanaxtriol    HPLC≥98%    20mg/支    1453-93-6
人參皂苷F1    Ginsenoside F1    HPLC≥98%    20mg/支    53963-43-2
人參皂苷F2    Ginsenoside F2    HPLC≥98%    20mg/支    62025-49-4
人參皂苷CK    Compound K    HPLC≥98%    20mg/支    39262-14-1
(R型)原人參二醇    Protopanaxdiol    HPLC≥95%    20mg/支    30636-90-9
人參皂苷Ro    Ginsenoside Ro    HPLC≥98%    20mg/支    34367-04-9
人參皂苷F3    Ginsenoside F3    HPLC≥98%    10mg/支    62025-50-7
人參皂苷Rg6    Ginsenoside Rg6    HPLC≥98%    20mg/支    
人參皂苷Rk1    Ginsenoside Rk1    HPLC≥95%    20mg/支    
人參二醇    Panaxadiol    HPLC≥98%    20mg/支    19666-76-3
人參三醇    Panaxtriol    HPLC≥98%    20mg/支    32791-84-7
原人參二醇    Protopanaxdiol    HPLC≥98%    20mg/支    30636-90-9
柴胡皂苷A    Saikosaponin A    HPLC≥98%    20mg/支    20736-09-8
柴胡皂苷C    Saikosaponin C    HPLC≥98%    20mg/支    20736-08-7
柴胡皂苷D    Saikosaponin D    HPLC≥98%    20mg/支    20874-52-6
柴胡皂苷B    Saikosaponin B    HPLC≥98%    20mg/支    
柴胡皂苷B1    Saikosaponin B1    HPLC≥98%    20mg/支    58558-08-0
柴胡皂苷B2    Saikosaponin B2    HPLC≥98%    20mg/支    58316-41-9
三七皂苷R1    Notoginsenoside R1    HPLC≥98%    20mg/支    80418-24-2
三七皂苷Ft1    Notoginsenoside Ft1    HPLC≥98%    20mg/支    
三七皂苷R2(R型)    20(S)-Notoginsenoside R2    HPLC≥94.50%    20mg/支    

Anti-ARK5     AMPK的相關(guān)蛋白激酶5抗體
Anti-ANP32C     致瘤磷蛋白32相關(guān)蛋白1抗體
Anti-AKIP     極光激酶A相互作用蛋白1抗體
Anti-ANKHD1     艾滋病病毒制約錨定蛋白抗體
Anti-Adenylate cyclase 1     腺苷酸環(huán)化酶1抗體
Anti-ABCE1     核糖核酸酶L抑制蛋白抗體
Anti-ARHGAP24     Rho GTP酶激活蛋白24抗體
Anti-ASAP3     GTP酶激活蛋白ASAP3抗體
Anti-ACTRIC/Activin A Receptor Type IC     激活素受體1C抗體
Anti-ADAMTS13     整合素樣金屬蛋白酶與凝血酶13型抗體
Anti-ADAM11   Anti-BPNT1/二磷酸3核苷酸酶抗體
Anti-ADAM12/MLTN     去整合素樣金屬蛋白酶12抗體
Anti-ADAM15     去整合素樣金屬蛋白酶15抗體
Anti-ADAM2     去整合素樣金屬蛋白酶2抗體
Anti-ADA/Adenosine deaminase     腺苷脫氨酶抗體
Anti-ASB4     含錨蛋白重復(fù)序列-細胞因子信號抑制物盒蛋白家族4抗體
Anti-ADORA1/Adenosine A1 Receptor     腺苷A1受體抗體
Anti-ApoER2     載脂蛋白E2受體抗體
Anti-AQP0/MIP26/LIM1     水通道蛋白0抗體
Anti-AP2 gamma     轉(zhuǎn)錄因子AP-2γ抗體
Anti-ANGPTL5     血管生成素相關(guān)蛋白5
Anti-ANGPTL6     血管生成素相關(guān)蛋白6抗體
Anti-AMH/MIS     Muellerian繆勒管激素抑制因子抗體
Anti-EphA8/Eph receptor A8     酪氨酸蛋白激酶受體A8抗體
Anti-APOL6    載脂蛋白樣蛋白6抗體
Anti-ARTS     凋亡相關(guān)蛋白TGFb信號抗體
Anti-ANKRD53     錨蛋白重復(fù)域53抗體
Anti-ANKRD54     錨蛋白重復(fù)域54抗體
Anti-AACS/ACSF1     脂肪酰輔酶A家族成員1抗體
Anti-A2LD1/GGACT     A2LD1蛋白抗體
Anti-A4GNT α1    4-N-乙酰葡糖胺轉(zhuǎn)移酶α4Gn-T抗體
Anti-AADAC     芳香乙酰胺脫乙?；缚贵w

公司嚴格的質(zhì)量控制，完善的庫存供應(yīng)體系，專業(yè)的銷售團隊和技術(shù)服務(wù)團隊，公司實力雄厚,有專業(yè)的科研隊伍,1000多個品種,銷售多個國家，專業(yè)化的抗體試劑開發(fā)、生產(chǎn)公司，有著一整套完整、規(guī)范的蛋白檢測及鑒定技術(shù)。為了適應(yīng)廣大生物醫(yī)學(xué)領(lǐng)域科研人員及學(xué)者對含錨蛋白重復(fù)序列estern Blotting 實驗日益增長的需求，本公司實驗室將提供Western Blotting的對外技術(shù)服務(wù)。我公司還可為您提供快速的、高質(zhì)量的和經(jīng)濟的多克隆抗體制備服務(wù)，并將成為您在科研及生產(chǎn)中的得力助手。我公司還免費提供真空冷凍抽干服務(wù)，得到凍干粉狀的抗體IgG產(chǎn)品，以便產(chǎn)品的使用及*保存。

我公司提供良好的產(chǎn)品售后服務(wù)，如有品質(zhì)量問題，經(jīng)售后核實后，本公司負責(zé)更換或退款，保證客戶的利益不受損失；另外還提供免費送貨*，歡迎廣大客戶訂購！